DABIGATRAN ETEXILATE MESYLATE (dabigatran etexilate mesylate) by Ichnos Glenmark Innovation is competitive, direct thrombin inhibitors. Approved for deep venous thrombosis, pulmonary embolism in adult patients, deep vein thrombosis and 11 more indications. First approved in 2024.
Drug data last refreshed 18h ago
competitive, direct thrombin inhibitors. Because thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of a thrombus. Both free and clot-bound thrombin, and thrombin-induced platelet aggregation are…
Worked on DABIGATRAN ETEXILATE MESYLATE at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants